FDMT•benzinga•
Goldman Sachs Maintains Buy on 4D Molecular Therapeutics, Lowers Price Target to $44
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 9, 2025 by benzinga